

Accepted Manuscript

Levetiracetam

Paul Howard, BMedSci, MRCP, Jan Remi, MD, Constanze Remi, MSc, Sarah Charlesworth, BPharm (Hons) DipClinPharm, MRPharmS, Helen Whalley, MSc, FRCP, Rebecca Bhatia, MRCP, Morwenna Hitchens, MRCP, Mary Mihalyo, BS, PharmD, RPh, Andrew Wilcock, DM, FRCP

PII: S0885-3924(18)30365-8
DOI: [10.1016/j.jpainsymman.2018.07.012](https://doi.org/10.1016/j.jpainsymman.2018.07.012)
Reference: JPS 9835

To appear in: *Journal of Pain and Symptom Management*

Received Date: 13 July 2018

Accepted Date: 13 July 2018

Please cite this article as: Howard P, Remi J, Remi C, Charlesworth S, Whalley H, Bhatia R, Hitchens M, Mihalyo M, Wilcock A, Levetiracetam, *Journal of Pain and Symptom Management* (2018), doi: 10.1016/j.jpainsymman.2018.07.012.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Therapeutic Reviews

Series Co-Editors: Andrew Wilcock, DM, FRCP, and Paul Howard BMedSci, MRCP

Therapeutic Reviews aim to provide essential independent information for health professionals about drugs used in palliative and hospice care. Additional content is available on www.palliativedrugs.com. Country-specific books (Hospice and Palliative Care Formulary USA, and Palliative Care Formulary, British and Canadian editions) are also available and can be ordered from www.palliativedrugs.com. The series editors welcome feedback on the articles (hq@palliativedrugs.com).

Levetiracetam**AHFS 28:12.92**

Paul Howard, BMedSci, MRCP, Jan Remi, MD, Constanze Remi, MSc, Sarah Charlesworth, BPharm (Hons) DipClinPharm, MRPharmS, Helen Whalley, MSc, FRCP, Rebecca Bhatia MRCP, Morwenna Hitchens MRCP, Mary Mihalyo, BS, PharmD, RPh, and Andrew Wilcock, DM, FRCP

Mountbatten Hospice (P.H.), Isle of Wight, United Kingdom; University Hospital of Munich, Germany (J.R. and C.R.), Nottingham University Hospitals (S.C.), Nottingham, United Kingdom; The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust (H.W.), United Kingdom; Dorothy House Hospice Care (R.B.), Wiltshire, United Kingdom; Prospect Hospice (M.H.), Swindon, United Kingdom; Mylan School of Pharmacy (M.M.), Duquesne University, Pittsburgh, Pennsylvania, USA and University of Nottingham (A.W.), Nottingham, United Kingdom

Correspondence to:

Dr Andrew Wilcock DM FRCP
Hayward House Macmillan Specialist Palliative Care Unit
Nottingham University Hospitals NHS Trust
Nottingham, United Kingdom, NG5 1PB.
andrew.wilcock@nottingham.ac.uk

© 2018 U.S. Cancer Pain Relief Committee. The scientific content of the article also appears on the website www.palliativedrugs.com, and is used with permission.

Class: Anti-epileptic (SV2A ligand).

Indications: Adjunctive therapy of focal or generalized myoclonic and tonic-clonic seizures; †monotherapy of focal seizures (Authorized in UK); †status epilepticus.

Pharmacology

Levetiracetam binds to synaptic vesicle protein SV2A, interfering with the release of the neurotransmitter stored within the vesicle. It gains access after neurotransmitter release as the vesicles are recycled. Thus, it selectively accumulates in, and inhibits, rapidly firing neurons.¹ Levetiracetam also inhibits potassium and N-type calcium channels.^{1,2}

Download English Version:

<https://daneshyari.com/en/article/10211840>

Download Persian Version:

<https://daneshyari.com/article/10211840>

[Daneshyari.com](https://daneshyari.com)